Arun Azad

Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial.

Edmond M Kwan, Lavinia Spain, Angelyn Anton, Chun L Gan, Linda Garrett, Deborah Chang, Elizabeth Liow, Caitlin Bennett, Tiantian Zheng, Jianjun Yu, Chao Dai, Pan Du, Shidong Jia, Heidi Fettke, Claire Abou-Seif, Gargi Kothari, Mark Shaw, Phillip Parente, Carmel Pezaro, Ben Tran, et al.

Journal article  |  2021  |  Eur Urol

BACKGROUND: Immune checkpoint inhibitor monotherapy in metastatic castration-resistant prostate cancer (mCRPC) has produced modest..

Efficacy of enzalutamide in subgroups of men with metastatic hormone-sensitive prostate cancer based on prior therapy, disease volume, and risk

Arun A Azad, Andrew J Armstrong, Antonio Alcaraz, Russell Z Szmulewitz, Daniel P Petrylak, Jeffrey Holzbeierlein, Arnauld Villers, Boris Alekseev, Taro Iguchi, Neal D Shore, Francisco Gomez-Veiga, Brad Rosbrook, Ho-Jin Lee, Gabriel P Haas, Arnulf Stenzl

Journal article  |  2021  |  PROSTATE CANCER AND PROSTATIC DISEASES

BACKGROUND: While enzalutamide plus androgen deprivation therapy (ADT) significantly reduces the risk of radiographic progression-..

The MURAL collection of prostate cancer patient-derived xenografts enables discovery through preclinical models of uro-oncology

Gail P Risbridger, Ashlee K Clark, Laura H Porter, Roxanne Toivanen, Andrew Bakshi, Natalie L Lister, David Pook, Carmel J Pezaro, Shahneen Sandhu, Shivakumar Keerthikumar, Rosalia Quezada Urban, Melissa Papargiris, Jenna Kraska, Heather B Madsen, Hong Wang, Michelle G Richards, Birunthi Niranjan, Samantha O'Dea, Linda Teng, William Wheelahan, et al.

Journal article  |  2021  |  NATURE COMMUNICATIONS

Preclinical testing is a crucial step in evaluating cancer therapeutics. We aimed to establish a significant resource of patient-d..

Androgens alter the heterogeneity of small extracellular vesicles and the small RNA cargo in prostate cancer

Elena S Martens-Uzunova, Gina D Kusuma, Stefania Crucitta, Hong Kiat Lim, Crystal Cooper, James E Riches, Arun Azad, Takahiro Ochiya, Glen M Boyle, Melissa C Southey, Marzia Del Re, Rebecca Lim, Grant A Ramm, Guido W Jenster, Carolina Soekmadji

Journal article  |  2021  |  JOURNAL OF EXTRACELLULAR VESICLES

Proliferation and survival of prostate cancer cells are driven by the androgen receptor (AR) upon binding to androgen steroid horm..

Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study

J Connor Wells, Shaan Dudani, Chun Loo Gan, Igor Stukalin, Arun A Azad, Elizabeth Liow, Frede Donskov, Takeshi Yuasa, Sumanta K Pal, Guillermo De Velasco, Aaron R Hansen, Benoit Beuselinck, Christian K Kollmannsberger, Thomas Powles, Bradley A McGregor, Mei S Duh, Lynn Huynh, Daniel YC Heng

Journal article  |  2021  |  CLINICAL GENITOURINARY CANCER

BACKGROUND: Limited data exist on the clinical effectiveness of second-line (2L) vascular endothelial growth factor (receptor) tar..

Real-world incidence of symptomatic skeletal events and bone-modifying agent use in castration-resistant prostate cancer - an Australian multi-centre observational study.

Angelyn Anton, Shirley Wong, Julia Shapiro, Andrew Weickhardt, Arun Azad, Edmond M Kwan, Lavinia Spain, Ashray Gunjur, Javier Torres, Phillip Parente, Francis Parnis, Jeffrey Goh, Marie C Semira, Peter Gibbs, Ben Tran, Carmel Pezaro

Journal article  |  2021  |  Eur J Cancer

INTRODUCTION: Bone metastases occur frequently in castration-resistant prostate cancer (CRPC) and may lead to skeletal-related eve..

177Lutetium PSMA-617 and idronoxil (NOX66) in men with end-stage metastatic castrate-resistant prostate cancer (LuPIN): Patient outcomes and predictors of treatment response of a Phase I/II trial.

Sarennya Pathmanandavel, Megan Crumbaker, Andrew O Yam, Andrew Nguyen, Christopher Rofe, Elizabeth Hovey, Craig Gedye, Edmond M Kwan, Christine Hauser, Arun A Azad, Peter Eu, Andrew J Martin, Anthony M Joshua, Louise Emmett

Journal article  |  2021  |  J Nucl Med

Background: 177Lutetium PSMA-617 (Lu-PSMA-617) is an effective therapy for metastatic castrate-resistant prostate cancer (mCRPC). ..

Independent prognostic impact of plasma NCOA2 alterations in metastatic castration-resistant prostate cancer

Heidi Fettke, Edmond M Kwan, Patricia Bukczynska, Jason A Steen, Maria Docanto, Nicole Ng, Phillip Parente, Andrew Mant, Siavash Foroughi, Carmel Pezaro, Christine Hauser, Tu Nguyen-Dumont, Melissa C Southey, Arun A Azad

Journal article  |  2021  |  PROSTATE

BACKGROUND: The androgen receptor (AR) pathway-associated gene nuclear receptor coactivator 2 (NCOA2) has an established oncogenic..

ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901)

Louise Emmett, Shalini Subramaniam, Anthony M Joshua, Megan Crumbaker, Andrew Martin, Alison Y Zhang, Nisha Rana, Ailsa Langford, Jenna Mitchell, Sonia Yip, Roslyn Francis, Michael S Hofman, Shahneen Sandhu, Arun Azad, Craig Gedye, Margaret McJannett, Martin R Stockler, Ian D Davis

Journal article  |  2021  |  BJU INTERNATIONAL

OBJECTIVES: To determine the activity and safety of lutetium-177 (177 Lu)-prostate-specific membrane antigen (PSMA)-617 in men wit..

THOR-707 (SAR444245), a novel not-alpha IL-2 as monotherapy and in combination with pembrolizumab in advanced / metastatic solid tumors: Interim results from HAMMER, an open-label, multicenter phase 1/2 Study.

Filip Janku, Raghad Abdul-Karim, Arun Azad, Johanna Bendell, Gerald Falchook, Hui K Gan, Tira Tan, Judy S Wang, Cheng Ean Chee, Lina Ma, Jill Mooney, Neyssa Marina, Giovanni Abbadessa, Marcos Milla, Tarek Meniawy

Conference Proceedings  |  2021  |  CANCER RESEARCH